Yttrium-90 Microspheres Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The Yttrium-90 Microspheres market is estimated to be valued at USD 650 million in 2025 and is expected to reach USD 1.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2032. This significant growth highlights the rising adoption of targeted cancer therapies and advances in microsphere technology, which are driving market expansion globally. Increasing prevalence of liver cancer and improvements in minimally invasive treatments further contribute to this robust market outlook.

Current market trends indicate a strong shift towards personalized medicine, with Yttrium-90 Microspheres playing a crucial role in selective internal radiation therapy (SIRT) for hepatic tumors. Innovations in microsphere materials and delivery mechanisms are enhancing treatment efficacy and patient outcomes. Additionally, growing investments in research and development, along with expanding healthcare infrastructure in emerging markets, are fostering adoption. Collaborations between biotech firms and medical institutions are expected to accelerate product innovations, making Yttrium-90 Microspheres a critical component of future oncological treatment paradigms.

Segmental Analysis:

By Product Type: Dominance of Resin Microspheres Driven by Versatility and Efficacy

In terms of By Product Type, Resin Microspheres contributes the highest share of the Yttrium-90 Microspheres market owing to its unique combination of clinical efficacy, ease of use, and flexible application protocols. Resin microspheres are favored in treatment due to their biocompatibility and ability to deliver targeted radiation effectively to tumor sites without significant collateral damage to healthy liver tissue. Their composition allows for better dosage control, enabling physicians to tailor treatments according to patient-specific parameters. Additionally, resin microspheres generally offer the advantage of a more uniform size distribution which enhances selective embolization capabilities. This precision reduces the risk of post-procedural complications and improves patient recovery times, making them a preferred choice in interventional oncology.

Another driver of growth in the resin microspheres segment is their well-established safety profile supported by extensive clinical studies over the years. They are often recommended in protocols for transarterial radioembolization (TARE), particularly for patients with unresectable liver tumors, further boosting their adoption. The availability of resin microspheres as a standardized product with consistent performance metrics also facilitates better integration in treatment regimens, making them attractive to healthcare providers globally. In contrast to glass microspheres, resin variants allow higher embolic load distribution, offering nuanced treatment efficacy in cases where tumor vascular anatomy varies. The continuous innovation in resin microsphere development, including improved radioactive loading techniques and packaging, also contributes to their sustained market leadership amid competition.

By Application: Primary Liver Cancer Leads Due to Rising Prevalence and Treatment Advancements

In terms of By Application, Primary Liver Cancer represents the largest segment within the Yttrium-90 Microspheres market, driven primarily by the increasing incidence of hepatocellular carcinoma worldwide and advancements in targeted therapies. Yttrium-90 microsphere therapy has emerged as a critical treatment option especially for patients who are not candidates for surgical resection or liver transplantation. The growing recognition of transarterial radioembolization as a minimally invasive approach that provides localized high-dose radiation directly to liver tumors, while sparing surrounding tissue, has enhanced clinical outcomes for primary liver cancer patients.

The segment benefits from improved diagnostic techniques enabling earlier detection of liver cancer, which in turn increases the pool of patients eligible for Yttrium-90 microsphere therapy. Additionally, the integration of yttrium-based microspheres with multimodal treatment plans—including chemotherapy and immunotherapy—has created new avenues for improving patient survival rates and quality of life. Medical research continuously validates the efficacy of this treatment in reducing tumor burden and managing disease progression, encouraging clinicians to utilize this modality more frequently. Epidemiological factors such as the prevalence of hepatitis B and C infections, key risk factors for primary liver cancer, reinforce the demand for effective localized treatments like Yttrium-90 microspheres, supporting the segment's dominant market position.

By End User: Hospitals Lead the Market Owing to Comprehensive Care and Technological Integration

In terms of By End User, Hospitals command the highest share in the market owing to their comprehensive infrastructure capable of performing complex Yttrium-90 microsphere therapies with multidisciplinary support. Hospitals offer an integrated clinical environment where oncologists, interventional radiologists, nuclear medicine specialists, and supportive care teams collaborate to deliver personalized cancer treatment. The presence of advanced imaging and radiation delivery equipment within hospital settings facilitates precise administration of microspheres, ensuring optimal therapy outcomes.

Hospitals also benefit from their ability to cater to a broad spectrum of patients, from initial diagnosis through post-treatment monitoring, which sustains high demand for Yttrium-90 microspheres. Their established referral networks and accessibility to specialized staff underpin their leading role in adopting new therapeutic technologies. Moreover, hospitals are often equipped to handle complex cases needing inpatient care and management of any adverse effects associated with radioembolization, further positioning them as the preferred end users in this segment.

Ambulatory surgical centers and specialized cancer treatment centers also contribute to growth, yet hospitals maintain dominance due to their comprehensive service offerings and capacity to conduct extensive research and clinical trials that validate and refine microsphere therapies. Investment in technological upgrades and expanding oncology departments within hospitals continues to create favorable conditions for the application of Yttrium-90 treatments, reinforcing their market leadership as key end user facilities.

Regional Insights:

Dominating Region: North America

In North America, the Yttrium-90 Microspheres market exhibits clear dominance driven by a mature healthcare infrastructure, extensive use of advanced medical technologies, and strong presence of leading pharmaceutical and biotech companies. The United States and Canada benefit from well-established regulatory frameworks that facilitate innovation and expedite approval processes for radiopharmaceuticals, including Yttrium-90 microspheres used in targeted cancer therapies such as liver cancer treatment via selective internal radiation therapy (SIRT). Furthermore, robust government funding for cancer research and supportive reimbursement policies contribute significantly to widespread adoption. Leading companies such as Sirtex Medical, BTG plc (a division of Boston Scientific), and Nordion Inc. have cemented their presence in North America, driving advancements in product innovation and expanding access through strategic partnerships with healthcare providers. The well-developed supply chain and logistics networks also ensure timely delivery and availability of these microspheres across hospitals and cancer treatment centers.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific region exhibits the fastest growth in the Yttrium-90 Microspheres market, attributable to rising cancer prevalence, increasing healthcare expenditure, and growing awareness of advanced treatment options. Countries such as China, Japan, India, and South Korea have been expanding their healthcare infrastructure rapidly, supported by government initiatives to improve cancer diagnosis and treatment capabilities. Additionally, the rising number of nuclear medicine centers and investments in radiopharmaceuticals have accelerated the adoption of Yttrium-90 microspheres. The region's growing middle-class population and improving health insurance coverage further encourage patients to seek superior cancer care. Key industry players like Sirtex Medical have been actively expanding their operations in Asia Pacific through collaborations and product registrations. Moreover, local companies such as Jubilant Life Sciences in India are enhancing the regional supply ecosystem by developing manufacturing and distribution channels, thereby reducing costs and increasing accessibility.

Yttrium-90 Microspheres Market Outlook for Key Countries

United States

The United States' market for Yttrium-90 microspheres is highly advanced, driven by the country's cutting-edge research institutions, regulatory support from the FDA, and extensive clinical adoption in oncology centers. Major players, including Sirtex Medical and Boston Scientific, have a strong foothold here, continuously launching innovative products and clinical trials that expand therapeutic indications. The presence of large cancer patient populations and excellent reimbursement frameworks make the U.S. a vital hub for both product development and commercialization, stimulating continual growth and innovation in this market.

China

China's market is rapidly expanding fueled by increasing government investments in healthcare infrastructure and expanding nuclear medicine departments in tertiary hospitals. The Chinese government's focus on cancer control programs and national insurance schemes has also facilitated easier patient access to advanced radiopharmaceutical therapies, including Yttrium-90 microspheres. International companies like Sirtex have entered joint ventures and distribution partnerships to tap into the vast market potential, while domestic firms are beginning to ramp up production capabilities, aiming to address local demand and reduce dependency on imports.

Japan

Japan continues to lead in Asia Pacific due to its highly developed healthcare system and early adoption of cutting-edge cancer treatments. The government encourages innovations in radiopharmaceuticals through streamlined regulatory pathways and supportive reimbursement mechanisms under its universal healthcare system. Leading companies such as BTG plc and Nordion have a well-established presence, providing access to a broad spectrum of microsphere therapies, while local research institutions actively engage in clinical studies to optimize these treatments for the Japanese patient population.

India

India's market for Yttrium-90 microspheres is growing, propelled by the rising burden of hepatic and other cancers and improvements in healthcare infrastructure, particularly in urban centers. The government's initiatives to increase awareness and provide cancer care access are complemented by growing private sector investments in nuclear medicine. Companies like Jubilant Life Sciences are instrumental in developing local manufacturing capabilities and forming partnerships with international corporations, helping to make these therapies more affordable and accessible across the country.

Germany

Germany's healthcare system, known for its high standards and comprehensive cancer care facilities, supports steady demand for Yttrium-90 microspheres. The country benefits from strong clinical expertise and research initiatives focused on advanced radiotherapy techniques. Siemens Healthineers and Eckert & Ziegler Radiopharma are among key players offering innovative solutions and maintaining a robust supply chain for Yttrium-90 microspheres. Regulatory support and well-structured reimbursement policies further encourage the integration of these microspheres into clinical oncology practice throughout Germany.

Market Report Scope

Market Segmentation

Product Type Insights (Revenue, USD, 2020 - 2032)

• Resin Microspheres
• Glass Microspheres
• Others

Application Insights (Revenue, USD, 2020 - 2032)

• Primary Liver Cancer
• Metastatic Liver Cancer
• Others

End User Insights (Revenue, USD, 2020 - 2032)

• Hospitals
• Ambulatory Surgical Centers
• Specialized Cancer Treatment Centers
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Sirtex Medical Limited
• BTG International Ltd.
• SIR-Spheres, an affiliate of Sirtex
• Terumo Corporation
• Nordion Inc.
• Cardinal Health
• Boston Scientific Corporation
• Curium Pharma
• MZ Radiopharmaceuticals
• Advanced Accelerator Applications (AAA, part of Novartis)
• Eckert & Ziegler AG
• Best Theratronics Ltd.
• Lantheus Holdings Inc.
• IBA Radiopharma Solutions
• Jubilant Radiopharma
• Ion Beam Applications (IBA)